{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:31:30Z","timestamp":1790685090400,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":680,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003Invasive fusariosis remains an aggressive, albeit infrequent infection in immunocompromised patients.<\/jats:p>\n               <jats:p>Methods. \u2003We identified all cases of invasive fusariosis between January 2002 and December 2014. We recorded patient characteristics including clinical presentation, treatment, and outcomes at 6 and 12 weeks after diagnosis, as well as species identification and antifungal drug susceptibilities.<\/jats:p>\n               <jats:p>Results. \u2003Fifteen patients were diagnosed with proven (12, 80%) or probable (3, 20%) fusariosis. Median age was 60 years (range, 26\u201378), and 10 patients were male. Underlying conditions included hematological malignancies (13, 87%), juvenile idiopathic arthritis (1, 7%), and third-degree burns (1, 7%). Five patients underwent hematopoietic stem-cell transplantation before diagnosis. Six patients (40%) received systemic glucocorticoids, and 11 patients (73%) had prolonged neutropenia at the time of diagnosis. Clinical presentations included the following: skin\/soft tissue infection (8, 53%), febrile neutropenia (4, 27%), respiratory tract infection (2, 13%), and septic arthritis (1, 7%). Twelve patients were treated with voriconazole: 6 (40%) with voriconazole alone, 4 (27%) with voriconazole and terbinafine, and 2 (13%) with voriconazole, terbinafine, and amphotericin. One patient (7%) was treated with terbinafine alone, and another with micafungin alone. Four patients underwent surgical debridement (4, 27%). Susceptibility testing was performed on 9 isolates; 8 demonstrated voriconazole minimum inhibitory concentrations \u22654 \u00b5g\/mL. The cumulative probability of survival was 66.7% and 53.3% at 6 and 12 weeks after diagnosis.<\/jats:p>\n               <jats:p>Conclusions. \u2003Mortality associated with invasive fusariosis remains high. Cumulative mortality at our center was lower than previous reports despite elevated voriconazole minimum inhibitory concentrations. Combination therapy should be studied systematically for fusariosis.<\/jats:p>","DOI":"10.1093\/ofid\/ofv099","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:40:56Z","timestamp":1436229656000},"source":"Crossref","is-referenced-by-count":62,"title":["Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience"],"prefix":"10.1093","volume":"2","author":[{"given":"Jessica M.","family":"Stempel","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital"},{"name":"Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Hammond","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"},{"name":"Harvard Medical School"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna A.","family":"Sutton","sequence":"additional","affiliation":[{"name":"Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Weiser","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M.","family":"Marty","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"},{"name":"Harvard Medical School"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,4]]},"reference":[{"key":"2020081009164413800_OFV099C1","first-page":"479","article-title":"Taxonomy, biology, and clinical aspects of Fusarium species","volume":"7","author":"Nelson","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"key":"2020081009164413800_OFV099C3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998\u20132009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"key":"2020081009164413800_OFV099C4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/383319","article-title":"Fusarium infection in hematopoietic stem cell transplant recipients","volume":"38","author":"Nucci","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00014-07","article-title":"Fusarium infections in immunocompromised patients","volume":"20","author":"Nucci","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2020081009164413800_OFV099C6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.mmcr.2014.05.002","article-title":"First case report of bloodstream infection by Rhizomucor pusillus in a child with hemophagocytic lymphohistiocytosis","volume":"5","author":"Dien Bard","year":"2014","journal-title":"Med Mycol Case Rep"},{"key":"2020081009164413800_OFV099C7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020081009164413800_OFV099C8","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/AAC.00176-08","article-title":"In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moliniforme) and Fusarium thapsinum","volume":"52","author":"Azor","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081009164413800_OFV099C9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jac\/dkn022","article-title":"Antifungal susceptibility profile of clinical Fusarium spp.: isolates identified by molecular methods","volume":"61","author":"Alastruey-Izquierdo","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2020081009164413800_OFV099C10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/17460913.3.1.9","article-title":"Use of terbinafine in rare and refractory mycoses","volume":"3","author":"Revankar","year":"2008","journal-title":"Future Microbiol"},{"key":"2020081009164413800_OFV099C11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1399-3062.2007.00296.x","article-title":"Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation","volume":"10","author":"Neuburger","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"2020081009164413800_OFV099C12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C14","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciu947","article-title":"Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients","volume":"60","author":"Garnica","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C16","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/AAC.00272-08","article-title":"Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from Northern Italy","volume":"52","author":"Tortorano","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081009164413800_OFV099C17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jama.296.8.953","article-title":"Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution","volume":"296","author":"Chang","year":"2006","journal-title":"JAMA"},{"key":"2020081009164413800_OFV099C18","first-page":"1068","article-title":"Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex","volume":"70","author":"Al-Hatmi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020081009164413800_OFV099C19","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.3390\/ijms12106722","article-title":"Molecular identification of Fusarium species in Gibberella fujikuroi species complex from rice, sugarcane and maize from Peninsular Malaysia","volume":"12","author":"Hsuan","year":"2011","journal-title":"Int J Mol Sci"},{"key":"2020081009164413800_OFV099C20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C21","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020081009164413800_OFV099C22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MD.0b013e318207612d","article-title":"Fusarium infection in lung transplant patients: report of 6 cases and review of the literature","volume":"90","author":"Carneiro","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2020081009164413800_OFV099C23","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.01618-06","article-title":"Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex","volume":"51","author":"Azor","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081009164413800_OFV099C24","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/AAC.46.10.3298-3300.2002","article-title":"In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results","volume":"46","author":"Paphitou","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081009164413800_OFV099C25","first-page":"1","article-title":"Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi","volume":"9","author":"Koehler","year":"2014","journal-title":"Crit Rev Microbiol"},{"key":"2020081009164413800_OFV099C26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/imj.12598","article-title":"Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haematopoietic stem cell transplantation, 2014","volume":"44","author":"Blyth","year":"2014","journal-title":"Intern Med J"},{"key":"2020081009164413800_OFV099C27","article-title":"Antifungal agents. Chapt 57","volume-title":"Goodman and Gillman's The Pharmacological Basis of Therapeutics, 12th Edition","author":"Bennett","year":"2011"},{"key":"2020081009164413800_OFV099C28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s10156-013-0594-9","article-title":"Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review","volume":"19","author":"Inano","year":"2013","journal-title":"J Infect Chemother"},{"key":"2020081009164413800_OFV099C29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.riam.2013.01.002","article-title":"Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium","volume":"30","author":"Spader","year":"2013","journal-title":"Rev Iberoam Micol"},{"key":"2020081009164413800_OFV099C30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2003.09.003","article-title":"In vitro interactions of licensed and novel antifungal drugs against Fusarium spp","volume":"48","author":"Ortoneda","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081009164413800_OFV099C31","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.jinf.2006.02.011","article-title":"Successful treatment of disseminated fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B","volume":"53","author":"Stanzani","year":"2006","journal-title":"J Infect"},{"issue":"(Suppl 1)","key":"2020081009164413800_OFV099C32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1470-9465.2004.00845.x","article-title":"Human fusariosis","volume":"10","author":"Dignani","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2020081009164413800_OFV099C33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/myc.12212","article-title":"Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance\u00ae registry","volume":"57","author":"Horn","year":"2014","journal-title":"Mycoses"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/3\/ofv099\/33621685\/ofv099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/3\/ofv099\/33621685\/ofv099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T13:22:18Z","timestamp":1597065738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofv099\/2460344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofv099","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015]]},"published":{"date-parts":[[2015]]},"article-number":"ofv099"}}